X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $9.3750.

Several equities research analysts have weighed in on XFOR shares. Guggenheim started coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Leerink Partners started coverage on X4 Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $12.00 target price for the company. Finally, Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock opened at $4.01 on Friday. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The stock has a market capitalization of $378.22 million, a price-to-earnings ratio of -0.88 and a beta of 0.34. The stock has a fifty day simple moving average of $4.13 and a two-hundred day simple moving average of $3.88. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.The business had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. On average, analysts predict that X4 Pharmaceuticals will post -0.77 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC lifted its stake in shares of X4 Pharmaceuticals by 6.7% during the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after purchasing an additional 423,196 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after purchasing an additional 114,915 shares during the last quarter. SummitTX Capital L.P. purchased a new stake in shares of X4 Pharmaceuticals during the 1st quarter worth $46,000. Virtu Financial LLC purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth $90,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth $173,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.